Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.
Aleksandr V KudriavtsevAnna V VakhrushevaNickolay A KryuchkovMaria E FrolovaKonstantin A BlagodatskikhTaras V IvanishinMilana DjonovicEkaterina A Romanovskaya-RomankoAnton N KovalenkoDmitry A LioznovTatiana G ZubkovaSvetlana V TeplykhRodion A OseshnyukMarina A StukovaArtur A IsaevIgor V KrasilnikovPublished in: Vaccines (2023)
RBD-Fc-based COVID-19 "Betuvax-CoV-2" vaccine in doses (20 + 5 µg and 20 + 20 µg) demonstrated an excellent safety profile and induced a strong humoral response. Further research on the protective effectiveness of the "Betuvax-CoV-2" vaccine for the prevention of COVID-19 is on its way.